Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Nat Chem. 2014 May 11;6(6):504–510. doi: 10.1038/nchem.1944

Figure 5.

Figure 5

Clonogenic survival curves and western blot analysis of cells treated with (–)-lomaiviticin A (1) or (–)-lomaiviticin C (2). a. Clonogenic survival curves for BRCA2-deficient VC8 and Peo1 cells and the corresponding isogenic cell lines transfected with and expressing a functional BRCA2 gene (VC8+BRCA2 and C4-2, respectively). Solid data points represent the BRCA2-proficient cell lines (VC8+BRCA2 and C4-2), unfilled data points represent the BRCA2-deficient cell lines (VC8 and Peo1). Left graphs: cells treated with 1. Right graphs: cells treated with 2. These data support DNA as the target of 1 and 2 as BRCA2 is involved in DNA repair and BRCA2-deficient cell lines are hypersensitive to DNA damaging agents (ref. 36). b. (–)-Lomaiviticin A (1) upregulates pATM and pChk2, but not pATR and pChk1, in MCF-7 cells. Western blot analysis of pATM, pATR, pChk2, Chk2, pChk1, and Chk1 in MCF-7 cells treated with 1 (10 or 20 pM). These data support production of DNA dsbs by 1 as pATM and pChk2 are involved in DNA dsb repair, while pATR and pChk1 respond primarily to replication fork stalling (ref. 37).